Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine
The presentation discusses various aspects of treatment strategies for newly diagnosed acute myeloid leukemia (AML), focusing on optimizing therapy approaches and providing practical insights for healthcare professionals. It delves into considerations for patients who are not suitable for intensive chemotherapy, explores the use of different approved or accessible agents, and emphasizes the importance of achieving transfusion independence and improved quality of life for AML patients.
The presentation also touches on specific mutations, such as IDH1, IDH2, and FLT3, and examines the efficacy and potential limitations of different treatment combinations. Overall, it aims to guide clinicians in making informed decisions for AML patients based on available data and therapeutic options.